Intensive Risk Factor Management and Cardiovascular Autonomic Neuropathy in Type 2 Diabetes: The ACCORD Trial.
Yaling TangHetal S ShahCarlos Roberto Bueno JuniorXiuqin SunJoanna MitriMaria SambataroLuisa SambadoUlagamadesan VenkatesanVivian A FonsecaAlessandro DoriaPradipta R RayPublished in: Diabetes care (2020)
These data confirm a beneficial effect of intensive glycemic therapy and demonstrate, for the first time, a similar benefit of intensive BP control on CAN in T2D. A negative CVD history identifies T2D patients who especially benefit from intensive glycemic control for CAN prevention.
Keyphrases
- glycemic control
- type diabetes
- blood glucose
- weight loss
- insulin resistance
- risk factors
- stem cells
- study protocol
- electronic health record
- heart rate variability
- clinical trial
- gene expression
- genome wide
- phase iii
- adipose tissue
- artificial intelligence
- bone marrow
- big data
- phase ii
- randomized controlled trial
- cell therapy
- deep learning
- dna methylation
- smoking cessation